DNTH
Dianthus Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$101.00-4.36%
Price as of Jul 20, 2026
DNTH valuation
Dianthus Therapeutics, Inc. valuation
Trailing, forward and enterprise-value multiples for the requested listing.
Forward multiples
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 2640.46x
Trailing multiples
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 4.60x
- Price / sales
- 4132.70x
- Price / cash flow
- -42.38x
Enterprise value
- Enterprise value
- $4.4B
- EV / sales
- 3301.94x
- EV / EBITDA
- -406.13x
- EV / EBIT
- -23.06x
- Market cap
- $5.5B
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.